- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03582839
Effects of an Internet Use Disorder and Internet Gaming Disorder Early Intervention Program (PROTECT+)
Background. In the last two decades Internet usage has grown vastly. Pathological Internet usage (IUD; Internet Use Disorder) is associated with severe mental health problems affecting social, academic and daily life functioning. Internet Gaming Disorder (IGD) has been already included in the DSM-V. Recently, the WHO declared to include Gaming Disorder (GD) in the upcoming ICD-11. Despite the increasing rates of adolescents with IUD and (I)GD, affected people are treated unsystematically and there is a lack of evidence based treatment programs. PROTECT+ is a low-threshold, cognitive behavioral short-term group intervention.
Methods. 54 patients, aged 9-19 years, received PROTECT+ intervention in Heidelberg, Germany. The PROTECT+ intervention group underwent a cognitive-behavioral 4-session group therapy. Follow-up data were collected at 1, 4, and 12 months after admission. Primary outcome was the change in (I)GD and IUD related symptoms at the 12-months follow-up. Secondary outcomes were changes in comorbid symptoms as well as in problem solving, cognitive restructuring and emotion regulation skills
Discussion. Treatment of IUD and IGD is still in its early stages. Recent reviews report increasing research on treatment but also a lack of well-designed studies and evidence based treatment programs. The PROTECT+ intervention is a theory driven and evidence based therapy program which is based on the PROTECT preventive intervention in school settings. In the intervention group a reduction of (I)GD and IUD symptom severity is expected over 12 months.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Adolescents aged 9 to 19 years Self-selection
Exclusion Criteria:
Severe comorbid mental health disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PROTECT+
The PROTECT+ intervention group is a self-selected sample, which receives the PROTECT+ group therapy (4 modules in 4 subsequent weeks à 100 min).
Participants are assessed at T1 (baseline), T2 (post treatment, 1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
|
The early intervention PROTECT+ consists of a cognitive-behavioral 4-session brief-protocol (100 minutes) and targets empirically identified risk factors of (I)GD/IUD, i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation.
It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in IUD symptom severity (self-report)
Time Frame: baseline, 1 month, 4-months, 12-months
|
IUD symptom severity is assessed by the Compulsive Internet Use Scale (CIUS; Meerkerk, Van Den Eijnden, Vermulst & Garretsen, 2009).
The CIUS is a broadly used and validated questionnaire including 14 Items assessing IUD.
|
baseline, 1 month, 4-months, 12-months
|
|
Changes in (I)GD/IUD symptom severity (self-report and parental report)
Time Frame: baseline, 1 month, 4-months, 12-months
|
(I)GD/IUD symptom severity is assessed via self-reports and via parental reports by the Video Game Dependency Scale (Computerspielabhängigkeitsskala; CSAS; Rehbein, Baier, Kleimann & Mößle, 2015).
The CSAS questionnaire has been adapted by including non-gaming IU.
|
baseline, 1 month, 4-months, 12-months
|
|
Changes in (I)GD/IUD symptom severity (Clinical Interview based on DSM-5)
Time Frame: 12-months
|
At 12-months follow-up, we conduct a clinical interview based on the criteria of IGD according to the DSM-5.
We adapted the criteria by non-gaming subtypes to assess IUD.
|
12-months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Emotion Regulation
Time Frame: baseline, 1 month, 4-months, 12-months
|
For the measurement of emotion regulation the German Questionnaire for Assessment of Emotion Regulation in Children and Adolescents (Fragebogen zur Erhebung der Emotionsregulation bei Kindern und Jugendlichen; FEEL-KJ; Grob & Smolenski, 2011) is used.
The questionnaire includes a measure of functional and dysfunctional emotion regulation strategies for the negative emotions fear, sadness and anger.
|
baseline, 1 month, 4-months, 12-months
|
|
Depressive Symptoms
Time Frame: baseline, 1 month, 4-months, 12-months
|
Depressive symptoms are assessed using the German Depression Inventory for Children and Adolescents (Depressionsinventar für Kinder und Jugendliche; DIKJ; Stiensmeier-Pelster, Braune-Krickau, Schürmann & Duda, 2014; Stiensmeier-Pelster, Schürmann & Duda, 1989).
The instrument allows for the detection and estimation of severity of depressive disorders according to the DSM-5 criteria (American Psychiatric Association, 2013).
|
baseline, 1 month, 4-months, 12-months
|
|
Comorbid emotional, oppositional, antisocial and attention deficit/ hyperactivity disorders
Time Frame: baseline, 1 month, 4-months, 12-months
|
Comorbid Psychopathology is assessed using the Strength and Difficulties Questionnaire (SDQ; Goodman, Meltzer & Bailey, 2003). It includes the 5 scales (1) emotional problems, (2) behavior problems, (3) hyperactivity/ attention deficits, (4) interpersonal problems with peers and (5) prosocial behavior and can be used for epidemiological research and as an indicator for emotional, oppositional, antisocial and attention deficit/ hyperactivity disorder. The Total Difficulties Score of the SDQ indicates the risk for developing a mental health disorder. |
baseline, 1 month, 4-months, 12-months
|
|
Anxiety Disorders: Social Anxiety
Time Frame: baseline, 1 month, 4-months, 12-months
|
We assess social anxiety using the German version of the Social Interaction Anxiety Scale (SIAS; Mattick & Clarke, 1998; Stangier, Heidenreich, Berardi, Golbs & Hoyer, 1999).
This questionnaire assesses anxiety in social interactions and allows for detection and the estimation of severity of social anxiety disorders.
|
baseline, 1 month, 4-months, 12-months
|
|
Anxiety Disorders: Performance and School Anxiety
Time Frame: baseline, 1 month, 4-months, 12-months
|
We assess performance and school anxiety with the 7th scale of the German adaption of the Fear Survey Schedule for Children - Revised (Phobiefragebogen für Kinder und Jugendliche; PHOKI Döpfner, Schnabel, Goletz & Ollendick, 2006; Muris & Ollendick, 2002).
|
baseline, 1 month, 4-months, 12-months
|
|
Procrastination
Time Frame: baseline, 1 month, 4-months, 12-months
|
Procrastination is assessed with the German Questionnaire for Procrastination (Allgemeiner Prokrastinationsfragebogen; APROF; Höcker, Engberding & Rist, 2013).
|
baseline, 1 month, 4-months, 12-months
|
|
Social Behavior and Learning Behavior
Time Frame: baseline, 1 month, 4-months, 12-months
|
For ratings of social competent behavior and academic motivation, we use the German Student Assessment List for Social and Learning Behavior (Schülereinschätzliste für Sozial- und Lernverhalten; SSL; Petermann & Petermann, 2014; Petermann, Petermann & Lohbeck, 2014).
|
baseline, 1 month, 4-months, 12-months
|
|
Self-Efficacy
Time Frame: baseline, 1 month, 4-months, 12-months
|
Self- efficacy is rated on the German Self-Efficacy Scale (Skala zu Allgemeinen Selbstwirksamkeitserwartung; SWE; Schwarzer & Jerusalem, 1999).
|
baseline, 1 month, 4-months, 12-months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Katajun Lindenberg, PhD, Institut für Psychologie der Pädagogischen Hochschule Heidelberg
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PH Heidelberg
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mental Disorder
-
Vincent AgyapongNova Scotia Health Authority; Dalhousie UniversityRecruitingGeneralized Anxiety Disorder | Major Depressive Disorder | Mental Health Wellness 1Canada
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophrenia | Major Depressive Disorder | Mental Disorder | Bipolar I DisorderUnited States
-
Brigham and Women's HospitalActive, not recruitingDepression | Mood Disorders | Depressive Disorder, Major | Psychiatric Disorder | Mental DisorderUnited States
-
Queen's UniversityCompleted
-
University of ManchesterRecruitingADHD | Mental Health | Autism | Neurodevelopment | Depression - Major Depressive Disorder | Anxiety Disorder (Panic Disorder or GAD)United Kingdom
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Brigham and Women's HospitalActive, not recruitingDepression | PTSD | Mood Disorders | Anxiety Disorders | OCD | Major Depressive Disorder | Psychiatric Disorder | Mental DisorderUnited States
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
University of OuluCompletedSeasonal Affective Disorder (SAD)Finland
-
Massachusetts General HospitalSamsung ElectronicsActive, not recruitingMood Disorders | Major Depressive Disorder | Mental Health IssueUnited States
Clinical Trials on PROTECT+
-
Lungpacer Medical Inc.CompletedAcute Respiratory Distress Syndrome | Ventilation Therapy; ComplicationsFrance
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH); Memorial Sloan Kettering Cancer... and other collaboratorsRecruitingDepression | Elder AbuseUnited States
-
Weill Medical College of Cornell UniversityThe Fan Fox & Leslie R. Samuels Foundation, Inc.; New York City Department... and other collaboratorsCompleted
-
Lund UniversityTerminated
-
LiveLeaf Inc.UnknownAntibiotic-associated Diarrhea
-
University of KragujevacPharmanova d.o.o., Obrenovac, SerbiaTerminatedAnemia | Renal Disease | Dialysis; ComplicationsSerbia
-
Lund UniversityCompletedAthletic Injuries | Health BehaviorSweden
-
University of MiamiEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedPregnancy | HIVSouth Africa
-
Pädagogische Hochschule HeidelbergDietmar Hopp StiftungUnknownMental Disorders